Lonza O6Z

SGD 79.97 +0.00% +0.00 Updated 12 Nov 2026, 17:16 SGT

Dividend history

Recorded rates may be provisional. Annual yields use today's price; they are not historical investment returns.

2026 year to date 2 records Yield at current price9.75% Annual dividend per shareSGD 7.80092652
Amount Ex Date Pay Date Particulars / source
CHF 2.50
Details Original source Reference: SG260414DVCAB0WL
CHF 2.50
Details Original source Reference: SG260414DVCAS6CD
2025 1 record Yield at current price7.80% Annual dividend per shareSGD 6.240741216
Amount Ex Date Pay Date Particulars / source
CHF 4.00
Details Original source Reference: SGX250502DVCAXIC
2024 1 record Yield at current price7.80% Annual dividend per shareSGD 6.240741216
Amount Ex Date Pay Date Particulars / source
CHF 4.00
Details Original source Reference: SGX240422DVCAAAG
2023 1 record Yield at current price6.83% Annual dividend per shareSGD 5.460648564
Amount Ex Date Pay Date Particulars / source
CHF 3.50
Details Original source Reference: SGX230328DVCAC5D
Annual totals, currencies and data coverage

Spot an error? Let us know.

Annual dividend per share is the calendar-year cash total, converted to the share-price currency using available exchange rates. Yield is that total divided by today's share price; it is not the historical investment return.

The current year is marked year to date. Its total includes ex-dates through today; future rows remain visible but are excluded. Amounts with missing data are unavailable, not zero.

Possible duplicate source records are shown together and can be expanded. Different confirmed references remain separate. Totals under review are withheld until the source identity is verified.

Free view: the latest five calendar years. Corporate-action dates are displayed as published; time-based summaries use SGT.

Earlier dividend history
10 earlier dividend records are hidden for non-members.

Background

Annual Report 2025 · Reviewed 2026-10-23 · Source dated 2026-04-01 · PDF p. 38

Lonza provides services and technologies through its Integrated Biologics, Advanced Synthesis and Specialized Modalities businesses. These are its reported continuing operating segments.

Full security profile